Cancer%20pain Signs and Symptoms

Signs and Symptoms

Introduction

Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival

Chronic pain syndrome also often occurs following cancer treatments

Pancreatic, head and neck cancer, and bone metastasis has a high prevalence of cancer pain
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they be screened and evaluated for pain

Definition

An unpleasant sensory and emotional experience due to actual or potential tissue damage in patients with cancer

SARS-CoV-2 Variants: Everything you need to know

01 Feb 2023

The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.

Carfilzomib-based triplet regimen a potential upfront treatment for high-risk MM

Pearl Toh, 22 Oct 2020

The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.